N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Eflornithine (Primary) ; Celecoxib; Cyclophosphamide; Topotecan
- Indications Neuroblastoma
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 11 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
- 11 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
- 11 Aug 2017 Status changed from recruiting to active, no longer recruiting.